Elisabeth Autret-Leca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabeth Autret-Leca has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
A.-P. Jonville-Béra
6 shared publications- Annie Pierre Jonville-Bera
Service de pharmacosurveillance, centre régional de pharmacovigilance Centre Val de Loire, CHRU, Tours, Tours, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)-UMR 1246, Tours, France
5 shared publications Annie-Pierre Jonville-Béra
CHRU de Tours, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le Médicament, Tours, France
5 shared publicationsL. Bensouda-Grimaldi
Service de pharmacologie clinique, centre régional de pharmacovigilance et d’information sur le médicament, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France
5 shared publications- Bruno Giraudeau
Université de Tours, Université de Nantes, SPHERE U1246, Inserm, Tours, France
4 shared publications - Lamiae Grimaldi-Bensouda
Department of Pharmacology, Hospital Group Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Paris, France
4 shared publications
Latest Publications
- 1 September 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (9) , 999-1001
Info-médicaments : spéciale néonatalogie
- 1 September 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (9) , 999-1001
Info-médicaments : spéciale néonatalogie
- 1 August 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (8) , 848-855
Pharmacovigilance en pédiatrie
- 1 August 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (8) , 848-855
Pharmacovigilance en pédiatrie
- 1 July 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (7) , 765-771
Info-médicaments
- 1 April 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (4) , 432-434
Infos médicaments : spécial néonatalogie
- 1 April 2012
- Published by Elsevier in Archives de Pédiatrie
- Vol. 19 (4) , 432-434
Infos médicaments : spécial néonatalogie
- 1 October 2011
- Published by Springer Nature in Pediatric Drugs
- Vol. 13 (5) , 317-324
Drug Exposure during the Periconceptional Period
Many studies have described the prescribing of drugs to pregnant women, but only very few have data concerning the periconceptional period specifically. The aim of the study was to evaluate the incidence of exposure to teratogenic drugs during early pregnancy and to determine whether a safer drug exists. In a French health insurances database, we analyzed drugs prescribed during the period starting 1 month before and ending 2 months after the beginning of pregnancy between 1 January 2006 and 31 December 2007. Based on the Summary of Product Characteristics (SPC), drugs we considered were those 'contraindicated', 'not recommended', 'to be avoided', and 'possible' for use during the first trimester of pregnancy. For drugs 'contraindicated', we established if there were alternatives with similar efficacy for the mother and lower risk for the fetus. Over a period of 2.25 years, 8754 drugs were prescribed to 1793 women starting 1 month prior to and ending 2 months after conception. Among these drugs, 20 (0.2%) were 'contraindicated', 195 (2.2%) were 'not recommended', and 1209 (13.8%) were 'to be avoided' during the first trimester of pregnancy. Twenty (1.1%) women received at least one drug that was 'contraindicated' during the first trimester, 171 (9.5%) received a drug that was 'not recommended' and 768 (42.8%) received a drug that was 'to be avoided'. At least one possible alternative was available for all except one 'contraindicated' drug. During the highest teratogenic risk period, 1.1% of women received a contraindicated drug, despite existence of a safer alternative drug. This may be partly accounted for by physicians not being aware of the pregnancy at the time the drug was administered and could be reduced by adding a section entitled 'women of child-bearing potential' to the SPC.
- 1 October 2011
- Published by Springer Nature in Pediatric Drugs
- Vol. 13 (5) , 317-324
Drug Exposure during the Periconceptional Period
Many studies have described the prescribing of drugs to pregnant women, but only very few have data concerning the periconceptional period specifically. The aim of the study was to evaluate the incidence of exposure to teratogenic drugs during early pregnancy and to determine whether a safer drug exists. In a French health insurances database, we analyzed drugs prescribed during the period starting 1 month before and ending 2 months after the beginning of pregnancy between 1 January 2006 and 31 December 2007. Based on the Summary of Product Characteristics (SPC), drugs we considered were those 'contraindicated', 'not recommended', 'to be avoided', and 'possible' for use during the first trimester of pregnancy. For drugs 'contraindicated', we established if there were alternatives with similar efficacy for the mother and lower risk for the fetus. Over a period of 2.25 years, 8754 drugs were prescribed to 1793 women starting 1 month prior to and ending 2 months after conception. Among these drugs, 20 (0.2%) were 'contraindicated', 195 (2.2%) were 'not recommended', and 1209 (13.8%) were 'to be avoided' during the first trimester of pregnancy. Twenty (1.1%) women received at least one drug that was 'contraindicated' during the first trimester, 171 (9.5%) received a drug that was 'not recommended' and 768 (42.8%) received a drug that was 'to be avoided'. At least one possible alternative was available for all except one 'contraindicated' drug. During the highest teratogenic risk period, 1.1% of women received a contraindicated drug, despite existence of a safer alternative drug. This may be partly accounted for by physicians not being aware of the pregnancy at the time the drug was administered and could be reduced by adding a section entitled 'women of child-bearing potential' to the SPC.
- 30 November 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (11) , 1596-1603
Infos médicaments
- 30 November 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (11) , 1596-1603
Infos médicaments
- 31 August 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (8) , 1237-1242
Molécules les plus innovantes des dernières années en pédiatrie : le médecin a-t-il des outils pour les identifier ?
- 31 August 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (8) , 1237-1242
Molécules les plus innovantes des dernières années en pédiatrie : le médecin a-t-il des outils pour les identifier ?
- 1 August 2010
- Published by Springer Nature in Drug Safety
- Vol. 33 (8) , 659-665
Isotretinoin Exposure during Pregnancy
Background: In three previous studies, we have shown that pregnant women were still being exposed to isotretinoin and that compliance with recommendations was incomplete. The relaxation of these recommendations (summary of product characteristics 2004), combined with the release of generic brands, encouraged us to carry out a fourth study. Objective: To assess isotretinoin exposure during pregnancy following the application of less stringent recommendations and the marketing of generic isotretinoin brands. Methods: All cases of isotretinoin exposure during pregnancy, between 1 January 2003 and 31 December 2006, spontaneously reported to pharmacovigilance centres, the Teratogenic Agent Information Centre, and pharmaceutical companies in France were assessed. Cases were classified for analysis into the following groups: ‘conception Results:Over 4 years, 147 cases of isotretinoin exposure during the teratogenic risk period were spontaneously reported, i.e. ‘conception Conclusions:We suggest that recommendations be tightened, with specific information regarding the most effective contraceptive method combined with compulsory monthly pregnancy testing during treatment. The French Drug Agency has informed the European Medicines Agency of the need for measures aimed at improving compliance.
- 1 August 2010
- Published by Springer Nature in Drug Safety
- Vol. 33 (8) , 659-665
Isotretinoin Exposure during Pregnancy
Background: In three previous studies, we have shown that pregnant women were still being exposed to isotretinoin and that compliance with recommendations was incomplete. The relaxation of these recommendations (summary of product characteristics 2004), combined with the release of generic brands, encouraged us to carry out a fourth study. Objective: To assess isotretinoin exposure during pregnancy following the application of less stringent recommendations and the marketing of generic isotretinoin brands. Methods: All cases of isotretinoin exposure during pregnancy, between 1 January 2003 and 31 December 2006, spontaneously reported to pharmacovigilance centres, the Teratogenic Agent Information Centre, and pharmaceutical companies in France were assessed. Cases were classified for analysis into the following groups: ‘conception Results:Over 4 years, 147 cases of isotretinoin exposure during the teratogenic risk period were spontaneously reported, i.e. ‘conception Conclusions:We suggest that recommendations be tightened, with specific information regarding the most effective contraceptive method combined with compulsory monthly pregnancy testing during treatment. The French Drug Agency has informed the European Medicines Agency of the need for measures aimed at improving compliance.